Cancer vaccinesBERD, David.Seminars in oncology. 1998, Vol 25, Num 6, issn 0093-7754, 103 p.Serial Issue

Ganglioside vaccines with emphasis on GM2LIVINGSTON, P.Seminars in oncology. 1998, Vol 25, Num 6, pp 636-645, issn 0093-7754Article

Perspective on allogeneic melanoma lysates in active specific immunotherapyMITCHELI, M. S.Seminars in oncology. 1998, Vol 25, Num 6, pp 623-635, issn 0093-7754Article

Cancer vaccines : Reborn or just recycled?BERD, D.Seminars in oncology. 1998, Vol 25, Num 6, pp 605-610, issn 0093-7754Article

Whole cell ELISA for detection of tumor antigen expression in tumor samplesERDILE, Lorne F; SMITH, Darlene; BERD, David et al.Journal of immunological methods. 2001, Vol 258, Num 1-2, pp 47-53, issn 0022-1759Article

Autologous, hapten-modified vaccine as a treatment for human cancersBERD, David.Vaccine. 2001, Vol 19, Num 17-19, pp 2565-2570, issn 0264-410XConference Paper

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responsesBERD, David; SATO, Takami; MASTRANGELO, Michael J et al.Cancer immunology and immunotherapy. 2002, Vol 51, Num 6, pp 320-326, issn 0340-7004, 7 p.Article

Ex vivo gene therapy using cytokine-transduced tumor vaccines : Molecular and clinical pharmacologySIMONS, J. W; MIKHAK, B.Seminars in oncology. 1998, Vol 25, Num 6, pp 661-676, issn 0093-7754Article

Heat-shock protein-based anticancer immunotherapy : An idea whose time has comeMENORET, A; CHANDAWARKAR, R.Seminars in oncology. 1998, Vol 25, Num 6, pp 654-660, issn 0093-7754Article

Active immunotherapy with allogeneic tumor cell vaccines : Present statusCHAN, A. D; MORTON, D. L.Seminars in oncology. 1998, Vol 25, Num 6, pp 611-622, issn 0093-7754Article

High-Dose Immunoembolization: Survival Benefit in Patients with Hepatic Metastases from Uveal Melanoma¹YAMAMOTO, Akira; CHERVONEVA, Inna; SATO, Takami et al.Radiology. 2009, Vol 252, Num 1, pp 290-298, issn 0033-8419, 9 p.Article

Active immunization against cancer cells : Impediments and advancesVELDERS, M. P; SCHREIBER, H; KAST, W. M et al.Seminars in oncology. 1998, Vol 25, Num 6, pp 697-706, issn 0093-7754Article

Interleukin 6 mediates production of interleukin 10 in metastatic melanomaTERAI, Mizue; ETO, Masumi; YOUNG, Garbo D et al.Cancer immunology and immunotherapy. 2012, Vol 61, Num 2, pp 145-155, issn 0340-7004, 11 p.Article

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine : Regression of pulmonary metastasesBERD, David; SATO, Takami; COHN, Herbert et al.International journal of cancer. 2001, Vol 94, Num 4, pp 531-539, issn 0020-7136Article

Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating FactorSATO, Takami; ESCHELMAN, David J; MASTRANGELO, Michael J et al.Journal of clinical oncology. 2008, Vol 26, Num 33, pp 5436-5442, issn 0732-183X, 7 p.Article

Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potentialTERAI, Mizue; TAMURA, Yutaka; ALEXEEV, Vitali et al.Cancer immunology and immunotherapy. 2009, Vol 58, Num 8, pp 1307-1317, issn 0340-7004, 11 p.Article

Autologous, hapten-modified vaccine as a treatment for human cancersBERD, D; KAIRYS, J; DUNTON, C et al.Seminars in oncology. 1998, Vol 25, Num 6, pp 646-653, issn 0093-7754Article

Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccineMAHIPAL, Amit; TERAI, Mizue; BERD, David et al.Cancer immunology and immunotherapy. 2011, Vol 60, Num 7, pp 1039-1045, issn 0340-7004, 7 p.Article

Whipsaw cancer treatments : The role of hormesis in endocrine and immune therapiesPREHN, Richmond T; BERD, David.Seminars in oncology. 2006, Vol 33, Num 6, pp 708-710, issn 0093-7754, 3 p.Article

Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapySATO, Takami; TERAI, Mizue; YASUDA, Rie et al.Cancer immunology and immunotherapy. 2004, Vol 53, Num 1, pp 53-61, issn 0340-7004, 9 p.Article

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccineBERD, David; SATO, Takami; MAGUIRE, Henry C et al.Journal of clinical oncology. 2004, Vol 22, Num 3, pp 403-415, issn 0732-183X, 13 p.Article

Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccineBERD, David.Vaccine. 2003, Vol 21, Num 7-8, pp 795-797, issn 0264-410X, 3 p.Conference Paper

Protracted survival after resection of metastatic uveal melanomaAOYAMA, Takekazu; MASTRANGELO, Michael J; BERD, David et al.Cancer. 2000, Vol 89, Num 7, pp 1561-1568, issn 0008-543XArticle

Immunization with virus-modified tumor cellsSCHIRRMACHER, V; AHLERT, T; PRÖBSTLE, T et al.Seminars in oncology. 1998, Vol 25, Num 6, pp 677-696, issn 0093-7754Article